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Abstract 
We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal 
residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 
and 2012. Two propensity score‑matched sample cohorts were created. We found that the addition of paclitaxel as a 
second intraperitoneal agent on a 3‑week dosing schedule did not yield significant incremental survival benefits over 
the intraperitoneal delivery of a single cisplatin‑based regimen. If our findings could be confirmed by a prospective 
randomized study, then it would be interesting to explore the efficacy of shifting back to a dose‑dense intraperitoneal 
delivery of paclitaxel or a dose‑dense delivery of a new formulation of paclitaxel for the patients with stage III epithe‑
lial ovarian, tubal, and peritoneal cancers.
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Background
Currently, the standard intraperitoneal chemotherapy 
protocol for the treatment of stage III epithelial ovarian, 
tubal, and peritoneal cancers follows that of the Gyneco-
logic Oncology Group (GOG) 114 trial (namely, intra-
peritoneal delivery of 100 mg/m2 of cisplatin on day 2) [1] 
or the GOG 172 trial (intraperitoneal delivery of 100 mg/
m2 of cisplatin on day 2 and intraperitoneal delivery of 
60  mg/m2 of paclitaxel on day 8) [2]. These protocols 
share a common intravenous delivery of 135  mg/m2 of 
paclitaxel on day 1. Importantly, the GOG 114 trial called 
for two cycles of a high dose of intravenous carboplatin 
(area under the curve, 9) before formal intraperitoneal 
treatment was administered. Although intraperitoneal 
chemotherapy has demonstrated superiority in the treat-
ment of ovarian cancer, in clinical practice the comple-
tion rate of six assigned intraperitoneal cycles reached 
only 71% in the GOG 114 trial and 42% in the GOG 172 
trial. Catheter-induced complications remain a major 
problem for patients who are unable to complete the 
assigned cycles [3].
In the present study, we compared the efficacy between 
GOG 114 and GOG 172 using survival as the primary 
end-point.
Patients and methods
We collected the clinical data of patients with stage III 
epithelial ovarian, tubal, and peritoneal cancer between 
January 2002 and December 2012 who were treated in 
the Institutional Review Board of Taipei Veterans Gen-
eral Hospital. Patients in the control cohort were treated 
according to the protocol described in the GOG 114 trial 
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[1]; patients in the experimental cohort were treated 
according to the protocol described in the GOG 172 trial 
[2]. A flow chart describing the screening and matching 
process is shown in Fig. 1.
We used a propensity score-matching technique 
to compare two intraperitoneally treated cohorts of 
patients. The technique of propensity score, which is a 
covariate summary score, was used for the analysis in the 
present study [4, 5].
The matching procedure involved a two-step analysis. 
In step 1, we used 10 conditioning variables to develop 
propensity scores. In step 2, we used an algorithm of the 
nearest neighbor matching within a specified caliper 
distance (0.25 σ in the current study, where σ was the 
standard deviation of logit of propensity score) without 
replacement to create matched samples [6, 7]. Thus, for 
a given patient in the experimental group, we identified 
all of the patients in the control cohort whose propensity 
scores lay within a specified distance of that of the patient 
in the experimental group. From this restricted set of 
control patients, we matched the patient in the control 
group whose propensity score was closest to that of the 
patient in the experimental group. Eventually, this cre-
ated two samples of equal size (1:1 matching).
We analyzed progression-free survival and overall sur-
vival in this study. All analyses were performed using 
STATA SE software, version 12 (Stata Corp., College Sta-
tion, Texas, USA). P values less than 0.05 were considered 
statistically significant.
Results
The Kaplan–Meier progression-free survival and over-
all survival curves are shown in Fig. 2, with both inten-
tion-to-treat and per-protocol analyses. The median 
Fig. 1 Flow chart of the screening and propensity score‑matching process
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progression-free survival showed no difference between 
the control cohort and the experimental cohort (inten-
tion-to-treat analysis: 21.7 vs. 23.3  months, P  =  0.646; 
per-protocol analysis: 21.6 vs. 26.8  months, P =  0.481). 
In addition, the median overall survival showed no sig-
nificant difference between these two cohorts (inten-
tion-to-treat analysis: 61.5 vs. 63.4  months, P  =  0.829; 
per-protocol analysis: 61.5 vs. 62.5  months, P  =  0.697) 
(Fig. 3). 
Discussion
Whether based on intention-to-treat analysis or per-
protocol analysis, we found no significant difference with 
respect to progression-free survival or overall survival 
between the control cohort and the experimental cohort. 
Our findings can be echoed by a detailed examination 
of the original GOG 114 and GOG 172 trials. In terms 
of progression-free survival, the advantage of median 
survival (intraperitoneal treatment group vs. intrave-
nous treatment group) was not significantly different for 
the GOG 114 and GOG 172 trials (6.0 months [27.9 vs. 
22.2 months] for the GOG 114 trial; 5.5 months [23.8 vs. 
18.3 months] for the GOG 172 trial). The overall survival 
was longer in the GOG 172 trial (11.0  months [63.2 vs. 
52.2  months] for the GOG 114 trial; 15.9  months [65.6 
vs. 49.7 months] for the GOG 172 trial). However, in the 
GOG 172 trial, patients were recruited between March 
1998 and January 2001; during this time, two drugs were 
available for second-line treatment: topotecan, which 
was approved in May 1996, and liposomal doxorubicin, 
which received accelerated approval in June 1999. These 
drugs may potentially extend post-progression survival 
and, thus, overall survival [8].
In summary, this propensity score-matching study of 
patients with stage III epithelial, tubal, and peritoneal 
cancers showed that patients in both the control cohort 
and the experimental cohort had similar survival out-
comes, suggesting that the addition of a second intra-
peritoneal paclitaxel dose (administered every 3  weeks) 
to the current standard platinum-based intraperitoneal 
chemotherapy regimen does not yield significant incre-
mental survival benefits. If our findings could be con-
firmed by a prospective randomized study, then it would 
be interesting to explore the efficacy of shifting back to 
a dose-dense intraperitoneal delivery of paclitaxel or a 
dose-dense delivery of a new formulation of paclitaxel for 
the patients with stage III epithelial ovarian, tubal, and 
peritoneal cancers.
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